BOCA RATON, Fla., Nov. 28, 2017 /PRNewswire/ -- The CNS Summit has released the 2017 CNS Summit Innovation Index. The CNS Summit Innovation Index ranks life science companies based on publicly available information, with regards to three facets of innovation: Trial Optimization, Digital Advancement, and Innovative Partnerships. The Index is powered by pharma innovation specialists IDEA Pharma.
The CNS Summit Innovation Index, launched at CNS Summit 2016, has, with this year's release, established itself as the key indicator of innovation in the life sciences. Key findings show the rise of Astra Zeneca, Boehringer Ingelheim, BMS, Celgene, and Bayer as emerging innovation leaders.
"The CNS Summit Innovation Index is a data-driven, neutral assessment of the digitization of the pharmaceutical industry," said Amir Kalali, Chief Curator and Scientific Program Chair. "We hope that it will encourage even more innovation."
Mike Rea, CEO, IDEA Pharma said, "The CNS Summit Innovation Index looks forward -- to the connection of possibilities, to the intersection of creativity, strategy, and technology, to companies beginning to behave like disruptors, rather than the disrupted."
The goal of the CNS Summit Innovation Index is to objectively assess investments made in innovation, encourage leadership in innovation, and allow companies to benchmark their innovation activities via an objective external source.
The CNS Summit, founded on the principles of Collaboration, Innovation, and Technology, is a community working collaboratively to shape the future of the life sciences. The CNS Summit 2017 is taking place November 16th—19th, 2017 in Boca Raton, Florida. For more information, visit www.cnssummit.org.
SOURCE CNS Summit